Thoracic surgical procedures

Quick Tube Medical Announces Revolutionary Chest Tubes to hit markets April 8th

Retrieved on: 
Wednesday, March 31, 2021
Medical specialties, Clinical medicine, Medicine, Thoracic surgical procedures, Pulmonology, Chest tube, Intensive care medicine, Thoracotomy, Catheter

FLETCHER, N.C., March 31, 2021 /PRNewswire-PRWeb/ --Leaders from Quick Tube Medical have just announced that the Company will begin delivering its one of a kind, FDA-registered standardized chest tube systems on April 8th.

Key Points: 
  • FLETCHER, N.C., March 31, 2021 /PRNewswire-PRWeb/ --Leaders from Quick Tube Medical have just announced that the Company will begin delivering its one of a kind, FDA-registered standardized chest tube systems on April 8th.
  • More than 1 million chest tubes are annually placed in the United States, and more than 4 million are placed worldwide.
  • In general terms, a "chest tube" is also known as a chest drain, thoracic catheter, tube thoracotomy, or intercostal drain.
  • According to Quick Tube Medical co-founder Ryan Luttrell, "Bringing Quick Tube Medical's chest tube to the medical marketplace is the highlight of my healthcare career.

Able Medical Devices Announces FDA Clearance of Valkyrie™ Thoracic Fixation System

Retrieved on: 
Tuesday, March 9, 2021
FDA, Surgery, Medical devices, Hospitals, Health, Thoracic surgical procedures, Clinical medicine, Medicine, Sternum, Median sternotomy, Bone fracture, Bone fractures, External fixation

Able Medical Devices, Inc. (Able) today announced the U.S. FDA 510(k) clearance of the Valkyrie Thoracic Fixation System.

Key Points: 
  • Able Medical Devices, Inc. (Able) today announced the U.S. FDA 510(k) clearance of the Valkyrie Thoracic Fixation System.
  • Valkyrie is intended for use in the stabilization and fixation of fractures of the chest wall, including sternal fixation following sternotomy, as well as sternal reconstructive surgical procedures for patients with normal and/or poor bone.
  • View the full release here: https://www.businesswire.com/news/home/20210309005279/en/
    The Valkyrie Thoracic Fixation System features the clinically proven performance of rigid fixation combined with the use of novel materials and the benefits of bioactive science to maximize sternal stability and promote bone healing.
  • Able Medical Devices is a leader in contract manufacturing and development.

Auris Health Announces Publication of Results from BENEFIT Study of MONARCH® Platform in CHEST

Retrieved on: 
Thursday, January 21, 2021
Medical specialties, Clinical medicine, Medicine, Pulmonology, Thoracic surgical procedures, Chest trauma, EBUS, Pneumothorax, Chest tube, Interventional pulmonology

The study, called BENEFIT, evaluated the safety and feasibility of the MONARCH Platform, a first-of-its-kind robotic technology indicated for use in diagnostic and therapeutic bronchoscopic procedures.

Key Points: 
  • The study, called BENEFIT, evaluated the safety and feasibility of the MONARCH Platform, a first-of-its-kind robotic technology indicated for use in diagnostic and therapeutic bronchoscopic procedures.
  • Results of the study were published in CHEST, the official publication of the American College of Chest Physicians.
  • The MONARCH Platform localized targeted nodules using a combination of direct visualization, navigational guidance and radial endobronchial ultrasound (R-EBUS).
  • Results of the study demonstrated safety, with pneumothorax occurring in 2/54 (3.7%) of procedures, and placement of a chest tube required in 1/54 (1.9%) procedure.

PleuraFlow Shown to Enable Improved Outcomes for Cardiac Surgery Patients in New Clinical Study Results

Retrieved on: 
Tuesday, October 20, 2020
Health, Medical devices, Surgery, General Health, Research, Science, Cardiology, Medical specialties, Clinical medicine, Medicine, Surgical specialties, Intensive care medicine, Thoracic surgical procedures, Cardiac surgery, Chest tube, Pulmonology, Tamponade, Cardiothoracic surgery, Surgery

The trial evaluated the use of the ClearFlows PleuraFlow Active Clearance Technology (ACT) System in the prevention of retained blood complications in heart surgery patients.

Key Points: 
  • The trial evaluated the use of the ClearFlows PleuraFlow Active Clearance Technology (ACT) System in the prevention of retained blood complications in heart surgery patients.
  • As cardiac surgeons, chest tube drainage is a routine part of guarding against tamponade after heart surgery.
  • We appreciate the opportunity to work globally with clinical teams in enabling enhanced recovery for cardiac surgery patients, said Paul Molloy, President and CEO of ClearFlow.
  • We look forward to continuing to support healthcare providers engaged in ERAS Cardiac and cardiac surgery outcomes improvement initiatives.

Insights on the Global Sternal Closure Devices Market to 2024 - Profiling A&E Medical, DePuy Synthes & Jace Medical Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, July 10, 2020
Health, General Health, Thoracic surgical procedures, Median sternotomy, Sternum, Marketplace

The "Global Sternal Closure Devices Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Sternal Closure Devices Market" report has been added to ResearchAndMarkets.com's offering.
  • This report provides a detailed description of the market for sternal closure devices.
  • The report also covers market projections through 2024 as well as market rankings for key market players.
  • Furthermore, the sternal closure devices market is segmented by procedure into median sternotomy, hemisternotomy and bilateral thoracosternotomy.

Acumed Welcomes Acute Thoracic Products to its Portfolio of Orthopaedic Solutions

Retrieved on: 
Tuesday, March 31, 2020
Thorax, Bone fracture, Medical specialties, Medicine, Surgery, Traumatology, Thoracic surgical procedures

The Acute product portfolio specifically offers surgeons solutions to address rib fractures associated with traumatic injury, as well as technologies for chest wall reconstruction.

Key Points: 
  • The Acute product portfolio specifically offers surgeons solutions to address rib fractures associated with traumatic injury, as well as technologies for chest wall reconstruction.
  • Acute's thoracic solutions will be integrated into the operations of Acumed to fully leverage the infrastructure and optimize best practices in quality affairs, marketing, medical education, manufacturing, and finance.
  • This integration allows Acumed to expand on the delivery of these premium products to all of our surgeon customers in general trauma, orthopaedic trauma, and thoracic surgery," commented Jagi Gill, Vice President of Business Development for Acumed.
  • Acumed is a global leader in developing innovative orthopaedic and medical solutions to improve patient care.

Global Thoracic Drainage Devices Market to Accumulate Revenues Worth US$ 980 Mn by 2027, Expanding at a CAGR of 5% Over 2019-2027: Transparency Market Research

Retrieved on: 
Friday, March 13, 2020
Medical specialties, Medicine, Clinical medicine, Pulmonology, Thoracic surgical procedures, Chest tube, Intensive care medicine, Drain, Compound annual growth rate

The total value of the global thoracic drainage devices market is projected to touch US$ 980 Mn by 2027, rising up from a value of US$ 615 Mn in 2018.

Key Points: 
  • The total value of the global thoracic drainage devices market is projected to touch US$ 980 Mn by 2027, rising up from a value of US$ 615 Mn in 2018.
  • The CAGR of the global thoracic drainage devices market is tabulated at 5% over the forecast period between 2019 and 2027.
  • This trend shall play a vital role in driving demand within the global thoracic drainage devices market.
  • Global Thoracic Drainage Devices Market: Business Landscape
    WHEN Medela AG's chest drainage system made its way into the market, several other manufacturers began investing in surgical research to develop premium technologies.

Global Thoracic Drainage Devices Market to Accumulate Revenues Worth US$ 980 Mn by 2027, Expanding at a CAGR of 5% Over 2019-2027: Transparency Market Research

Retrieved on: 
Friday, March 13, 2020
Medical specialties, Medicine, Clinical medicine, Pulmonology, Thoracic surgical procedures, Chest tube, Intensive care medicine, Drain, Compound annual growth rate

The total value of the global thoracic drainage devices market is projected to touch US$ 980 Mn by 2027, rising up from a value of US$ 615 Mn in 2018.

Key Points: 
  • The total value of the global thoracic drainage devices market is projected to touch US$ 980 Mn by 2027, rising up from a value of US$ 615 Mn in 2018.
  • The CAGR of the global thoracic drainage devices market is tabulated at 5% over the forecast period between 2019 and 2027.
  • This trend shall play a vital role in driving demand within the global thoracic drainage devices market.
  • Global Thoracic Drainage Devices Market: Business Landscape
    WHEN Medela AG's chest drainage system made its way into the market, several other manufacturers began investing in surgical research to develop premium technologies.

First Study of Thoraguard Digital Drainage System Completed at Stanford University Medical Center

Retrieved on: 
Tuesday, January 21, 2020
Health, Medical devices, Technology, Surgery, Software, Clinical trials, Cardiology, Medical specialties, Medicine, Clinical medicine, Intensive care medicine, Pulmonology, Thoracic surgical procedures, Surgical specialties, Chest tube, Coronary artery bypass surgery, Cardiac surgery, Surgery, Cardiothoracic anesthesiology, Thoraguard, Centese

Centese, Inc. today announced completion of the first clinical study of its Thoraguard digital drainage system used in cardiac surgery at Stanford University Medical Center.

Key Points: 
  • Centese, Inc. today announced completion of the first clinical study of its Thoraguard digital drainage system used in cardiac surgery at Stanford University Medical Center.
  • We are enthusiastic about studying this new digital drainage system designed to clear chest tubes automatically.
  • The Stanford study encompassed 25 patients undergoing non-emergent cardiac surgery, such as coronary artery bypass surgery or heart valve replacement, with whom Thoraguard was used as the exclusive post-operative drainage system.
  • Thoraguard is a next-generation digital drainage system designed to protect patients and improve the accuracy of post-operative clinical decision-making.

ClearFlow Announces Positive Randomized Controlled Trial Results and Inclusion in ERAS Guideline Recommendations

Retrieved on: 
Tuesday, May 7, 2019
Health, Cardiology, Clinical trials, Medical devices, Medical specialties, Medicine, Clinical medicine, Intensive care medicine, Pulmonology, Thoracic surgical procedures, Surgical specialties, Chest tube, Heart, Cardiac surgery, Surgery

This new data stems from a trial evaluating the use of ClearFlows PleuraFlow Active Clearance Technology (ACT) System in heart surgery patients at the Montreal Heart Institute.

Key Points: 
  • This new data stems from a trial evaluating the use of ClearFlows PleuraFlow Active Clearance Technology (ACT) System in heart surgery patients at the Montreal Heart Institute.
  • PleuraFlow is a medical device used at the bedside in the ICU that enables caregivers to actively maintain chest tube patency following cardiac surgery.
  • A patent chest tube enables evacuation of blood and fluid from the operative site after closure of the surgical wound and reduces retained blood.
  • This prospective randomized controlled clinical trial, presented at AATS by Dr. Samuel St-Onge, demonstrated a statistically significant reduction in chest tube clogging and emergency reoperations for retained blood, and a directional reduction in POAF.